NcXHF

ASSURING QUALITY CANCER SURVIVORSHIP CARE: WE’VE ONLY JUST BEGUN
TABLE 2. Minimum Data Elements to Be Included in a Survivorship Care Plan
Treatment Summary
Contact information of the treating institutions and providers
Specific diagnosis, including histologic subtype, when relevant
Stage of disease at diagnosis
Surgery (yes/no); if yes:
Surgical procedure with location on the body
Date(s) of surgery (year required, month optional, day not required)
Chemotherapy (yes/no); if yes:
Names of systemic therapy agents administered (listing individual names rather than regimens)
End date(s) of chemotherapy treatment (year required, month optional, day not required)
Radiation (yes/no); if yes:
Anatomic area treated by radiation
End date(s) of radiation treatment (year required, month optional, day not required)
Ongoing toxicity or side effects of all treatments received at the completion of treatment (Any information concerning the likely course of recovery from these
toxicities should also be covered)
For selected cancers, genetic/hereditary risk factor(s) or predisposing conditions and genetic testing results, if performed
Follow-up Care Plan
Oncology team member contacts, with location of the treatment facility (repeat only if separate document)
Need for ongoing adjuvant therapy for cancer
Adjuvant therapy name
Planned duration
Expected side effects
Schedule of follow-up–related clinical visits (to include who will provide the follow-up visit and how often and where this will take place)
Cancer surveillance tests for recurrence (to include who is responsible for ordering/carrying out the test, the frequency of testing, and where this will take
place)
Cancer screening for early detection of new cancers, to be included only if different from the general population (to include who is responsible for carrying out
screening, the frequency of testing, and where this will take place)
Other periodic testing and examinations (Rather than outlining specific testing, the group suggested an inclusion of a general statement to continue all
standard non–cancer-related health care with your primary care provider, with the following exceptions: if there are any)
Possible symptoms of cancer recurrence (Rather than including a list of possible symptoms, the group suggested inclusion of a general statement, Any new,
unusual, and/or persistent symptoms should be brought to the attention of your provider)
A list of likely or rare but clinically significant late effects and/or long-term effects, if known, that a survivor may experience based on his or her individual
diagnosis and treatment (including symptoms that may indicate the presence of such conditions)
A list of items (eg, emotional or mental health, parenting, work/employment, financial issues, and insurance) should be covered with standard language stating
that survivors have experienced issues in these areas and that the patient should speak with his or her oncologist and/or primary care provider for
related concerns. Include a list of local and national resources to assist the patient in obtaining the proper services
A general statement emphasizing the importance of healthy diet, exercise, smoking cessation, and alcohol use reduction may be included. Statements may be
tailored if particularly pertinent to the individual
This information is available at www.facs.org/publications/newsletters/coc-source/special-source/standard33. 43 For the ASCO SCP templates and other survivorship resources, visit www.asco.org.
new issues that must be dealt with for successful implementation.
Since the 2006 IOM report, the rapid development of
health information technology has increasingly fostered the
ability to deliver value-based cancer care. 11 To that end, the
Health Information Technology for Economic and Clinical
Health (HITECH) Act of 2009 promotes the adoption and
meaningful use of EHRs. Based on data from the American
Hospital Association, 85% of acute care hospitals had certifıed
EHRs that met Federal requirements for meaningful use
by 2012, with variation by state. 12 This current adoption of
EHRs is a dramatic increase from 9.4% in 2008. 12 An important
aspect of use will be the interoperability among EHRs to
allow data exchange in a meaningful way. Here is where the
SCP will be critical as an important tool for care coordination
and in sharing a concise history of patient diagnosis, summary
of treatments received, surveillance plan, and management
of the consequences of cancer and its treatment.
One component of valuable EHRs is the ability to have
oncology-specifıc clinical decision support systems [CDSS]
that draw on created knowledge bases and patient data,
which have the potential to tailor decisions across of the cancer
continuum. 11,13 CDSS have rules, alerts, and workflow
tools that can be used for the development of SCPs. This includes
the integration of CPGs, such as surveillance recommendations
with patient data to create the SCP. Other ways
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e585